Allogene
Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy
Richard Staines
Allogene, CAR T, Gilead, Kite Pharma, non-Hodgkin lymphoma, Oncology
0 Comment
Century gets $250m to develop next-gen ‘off the shelf’ cancer cell therapies
Richard Staines
Allogene, CAR T, Century Therapeutics, Oncology
0 Comment
Allogene raises another $120m to develop ‘off-the-shelf’ CAR-Ts
Richard Staines
Allogene, blood cancer, cancer, CAR T, Cellectis, Pfizer
0 Comment
Startup biotech already raised $300m earlier this year
News/ News/ News/ Oncology/ R&D/ R&D/ US
Ex-Kite chiefs’ biotech to research ‘off-the-shelf’ CAR-Ts with Cellectis
Richard Staines
Allogene, cancer, CAR T, Cellectis, Gilead, Kite Pharma
0 Comment
Belldegrun and Chang’s Allogene to take over from Pfizer in R&D deal